Atrial natriuretic peptide in liver cirrhosis with mild ascites

Gastroenterologia Japonica - Tập 25 - Trang 356-362 - 1990
Shuichi Miyase1, Shigetoshi Fujiyama1, Hideto Chikazawa1, Tatsuo Sato1
1Third Department of Internal Medicine, Kumamoto University Medical School, Kumamoto, Japan

Tóm tắt

To clarify the involvement of atrial natriuretic peptide (ANP) in the pathogenesis of liver cirrhosis, we measured plasma ANP in patients with various stages of cirrhosis and in age-matched normal subjects. Urinary cyclic guanosine monophosphate (cGMP) was also measured as a marker of active biological ANP. In addition, effects of exogenous synthetic human ANP (0.5 Μg/kg) on renal functions were examined in normal subjects and in cirrhotics without ascites or with mild ascites. Plasma ANP levels were not significantly different among these 3 groups. Urinary cGMP concentrations were significantly higher in both cirrhotics without ascites and cirrhotics with mild ascites, (340 pmol/ml, P<0.05 and 496 pmol/ml, P<0.01 respectively) than normal subjects (95 pmol/ml). In normal subjects, marked increases in urinary volume (UV), sodium excretion (UNaV), fraction excretion of sodium (FENa) and free water clearance (CH2O) were induced after ANP infusion, and significant recoveries were subsequently observed in these parameters. However, in cirrhotics, the responses to ANP infusion of UV, FENa and CH2O were far less dramatic. The response of UV, UNaV and FENa in cirrhotics with mild ascites was delayed compared to cirrhotics without ascites. These results suggest that the blunted natriuretic responsiveness to ANP is contributory to the pathogenesis of initial sodium retention in cirrhotics.

Tài liệu tham khảo

Epstein M: Renal sodium handling in cirrhosis; In: Epstein M, ed. The kidney in liver disease, 3rd ed, Williams & Wilkins, Baltimore. 1988;3–30

Anderson JV, Donckier J, Mckenna WJ, et al: The plasma release of atrial natriuretic peptide in man. Clin Sci 1986;71:151–155

Richards AM, Nicholls MG, Irkam H, et al: Renal, hemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1985;l:545–549

Cody RJ, Atlas SA, Laragh JH, et al: Atrial nartiuretic factor in normal subjects and heart failure patients. J Clin Invest 1986;78:1362–1374

Richards AM, Tonolo G, Montorisa P, et al: Low dose infusions of 26-and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrinol Metab 1988;66:465–472

Morgan TR, Imada T, Hollister AS, et al: Plasma human atrial natriuretic factor in cirrhosis and ascites with and without functional renal failure. Gastroenterology 1988;95:1641–1647

Gines P, Jimenez W, Arroyo V, et al: Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988;8:636–642

Fukui H, Tsujii T, Matsumura M, et al: Plasma levels of atrial natriuretic peptide in patients with liver cirrhosis and its relation to ascites and renal function. Gastroenterol Jpn 1989;24:149–155

Uemura K, Oguchi H, Kiyosawa K, et al: Plasma human atrial natriuretic peptide levels in patients with liver. J Gastroenterology and Hepatology 1989;4:167–174

Epstein M, Loutzenhiser R, Norsk P, et al: Relationship between plasma ANF responsiveness and renal sodium handling in cirrhotic humans. Am J Nephrol 1989;9:133–143

Gerbes AL, Wernze H, Arendt RM, et al: Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989;9:417–422

Brabant G, Jüppner H, Kirschner M, et al: Human atrial natriuretic Peptide for the treatment of patients with liver cirrhosis and ascites. Klin Wochenschr 1986;64:108–111

Salerno F, Badalamenti S, Incerti P, et al: Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis. Hepatology 1988;8:21–26

Laffi G, Pinzani M, Meacci E, et al: Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology 1989;96:167–177

Naomi S, Umeda T, Iwaoka T, et al: A sensitive radioimmunoassay of human atrial natriuretic polypeptide using monoclonal antibody recognizing human form ring structure. Life sci 1988;43:761–768

Ohhashi M, Fujio N, Nawata H, et al: High plasma concentrations of human atrial natriuretic poly peptide in aged man. J Clin Endoclinol Metab 1987;64:81–85

Haller B. Ziist H, Shaw S, et al: Effects of posture and ageing on circulating atrial natriuretic peptide levels in man. J Hypertension 1987;5:551–556

Gerzer R, Witzgall H, Tremblay J, et al: Rapid increase in plasma and urinary cyclic GMP after bolus injection of atrial natriuretic factor in man. J Clin Endocrinol Metab 1985;61: 1217–1219

Liebermann FL, Denison EK, Reynolds TB: The relationship of plasma volume, portal hypertention, asctes, and renal sodium retention in cirrhosis: The overflow theory of ascites formation. Ann Ny Acad Sci 1970;170:202–206

Bernardi M, Trevisani F: Sodium metabolism in cirrhosis. In: Arroyo V, Bernardi M, Epstein M et al: ed. Pathophysiology of ascites and functional renal failure in cirrhosis. J of Hepatol 1988;6:239–257

Trevisani F, Bernardi M, Palma RD, et al: Circadian variation in renal sodium and potassium handling in cirrhosis. Gastroenterology 1989;96:1187–1198

Hirata Y, Tomita M, Takada S, et al: Vascular receptor binding activities and cyclic GMP responses by synthetic human and rat atrial natriuretic peptide(ANP) and receptor down regulation by ANP. Biochem Biophys Res Commun 1985;128:538–546

Thông tin
Thông tin xuất bản

Gastroenterologia Japonica

Tập 25

356-362

Thông tin tác giả